Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.49 |
| ▸ | HCN4 | Q9Y3Q4 | 2/20 | 0.49 |
| ▸ | HCN1 | O60741 | 1/20 | 0.49 |
| ▸ | HCN3 | Q9P1Z3 | 1/20 | 0.49 |
| ▸ | HCN2 | Q9UL51 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 12/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358768 | 0.92 | P2RX7 (0.52) | P2RX7HCN4HCN1HCN3HCN2 | |
| SCHEMBL13706846 | 0.90 | HCN4 (0.59) | P2RX7HCN4HCN1IL1BSLC6A9 | |
| SCHEMBL4523000 | 0.89 | P2RX7 (0.46) | P2RX7HCN4HCN1HCN3HCN2 | |
| SCHEMBL4538239 | 0.89 | P2RX7 (0.46) | P2RX7HCN4HCN1HCN3HCN2 | |
| SCHEMBL13706930 | 0.89 | HCN4 (0.51) | P2RX7HCN4HCN1IL1BSLC6A9 | |
| SCHEMBL13706839 | 0.88 | HCN4 (0.52) | P2RX7HCN4HCN1IL1BSLC6A9 | |
| SCHEMBL4531474 | 0.86 | P2RX7 (0.47) | P2RX7HCN4IL1B | |
| SCHEMBL4360116 | 0.85 | P2RX7 (0.49) | P2RX7HCN4HCN1HCN3HCN2 | |
| SCHEMBL4354591 | 0.85 | P2RX7 (0.52) | P2RX7HCN4HCN1HCN3HCN2 | |
| SCHEMBL4351906 | 0.83 | P2RX7 (0.49) | P2RX7HCN4HCN1HCN3HCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | claimed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |